How I treat type 2 variant forms of von Willebrand disease
Type 2 von Willebrand disease (VWD) includes a wide range of qualitative abnormalities of von Willebrand factor structure and function resulting
Neuroblastoma – Paradigm for Precision Medicine
15:10
סגור לתגובות על Neuroblastoma – Paradigm for Precision Medicine
Meredith S. Irwin, MD, Julie R. Park, MD
Pediatr Clin N Am 62 (2015) 225–256
Hematopoietic Cell Transplantation and Cellular Therapeutics in the Treatment of Childhood Malignancies
14:40
סגור לתגובות על Hematopoietic Cell Transplantation and Cellular Therapeutics in the Treatment of Childhood Malignancies
Mallhi, Kanwaldeep; Lum, Lawrence G; Schultz, Kirk R; Yankelevich, Maxim
Pediatric clinics of North America, Vol: 62, Issue: 1,
Brain Tumors
10:26
סגור לתגובות על Brain Tumors
Murali Chintagumpala, MD, Amar Gajjar, MD
Pediatr Clin N Am 62 (2015) 167–178
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment
16:50
סגור לתגובות על EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment
Annals of Oncology, Volume 26, Issue 2, 1 February 2015, Pages 407–414
Treatment of Pediatric Acute Lymphoblastic Leukemia
12:54
סגור לתגובות על Treatment of Pediatric Acute Lymphoblastic Leukemia
Stacy L. Cooper, MD, Patrick A. Brown, MD., Pediatric clinics of North America, Vol: 62, Issue: 1, Page:
A Randomized, Open-label, Controlled Phase 3 Adaptive Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia | ALL
14:57
אין תגובות
Amgen Protocol Number 20120215
EudraCT number 2014-002476-92
How we treat chronic graft-versus-host disease
15:23
סגור לתגובות על How we treat chronic graft-versus-host disease
Mary E. D. Flowers and Paul J. Martin
Blood 2015 125:606-615
